PainReform (PRFX)

• Market cap: $4.64M
• 1 day: -52.51%
• 5 days: 63.08%
• 1 month: 27.40%
• 3 months: 72.08%
• 6 months: -53.06%
• Year to date: -91.44%
• 1 year: -91.10%
• 5 years: -99.67%
• 10 years: -99.67%

About: PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.

Employees: 7

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 4 [Q2] → 4 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

7.21% less ownership

Funds ownership: 12.19% [Q2] → 4.98% (-7.21%) [Q3]

76% less capital invested

Capital invested by funds: $145K [Q2] → $35.2K (-$110K) [Q3]